Panama reopens talks about the future of a controversial copper mine, but opposition remains
Pitcher Julio Urías suspended through the All-Star break by MLB under domestic violence policy
Andrew Tate en route to Romania to meet legal obligations pending trafficking probe
Serbia deputy prime minister says Russian spies help put down protests
TSX drops as tariff worries persist
US scraps sanctions on Tornado Cash, crypto ‘mixer’ accused of laundering North Korea money
Kyan Evans and favored No. 12 seed Colorado State beat short-handed Memphis 78-70 in March Madness
Car show organized in Whitman, Massachusetts, for an 11-year-old boy battling cancer
(Reuters) - Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
The U.S. initial public offering market is in the early innings of a recovery on hopes of potential interest-rate cuts and lower market volatility.
Zenas BioPharma, an immunology and inflammation focused biopharma company, said it has raised $358.3 million from investors since its inception.
The company's investors include Tellus BioVentures, Fairmount, Norwest Venture Partners, Enavate Sciences and Bristol-Myers Squibb.
The firm's losses widened to $65.8 million for the six months ended June 30, compared with $48.1 million, a year earlier. It did not reveal the number of shares it planned to sell and the proposed price range.
The company expects its shares to trade on the Nasdaq Global Market under the ticker symbol 'ZBIO'. Morgan Stanley, Jefferies, Citigroup and Guggenheim Securities are the underwriters.
(Reporting by Manya Saini in Bengaluru; Editing by Arun Koyyur)
